1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novo Nordisk Halts Phase III Concizumab Hemophilia Trials After Three Thrombotic Events

 
• By Mandy Jackson

No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.

Hand above a red emergency button
Novo Nordisk halted three studies, including two Phase III trials • Source: Shutterstock

Novo Nordisk AS has halted one Phase II and two Phase III clinical trials for concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) in the treatment of hemophilia A and B, due to non-fatal adverse thrombotic events observed in three patients in the Phase III program. Development of at least four other drug candidates designed to inhibit TFPI have been suspended to date, but so far Novo Nordisk has not decided to discontinue concizumab development entirely.

The Danish company said on 16 March that it has stopped enrolling patients in the trials and noted that treatment will be discontinued for individuals already enrolled in the studies

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D